MX9302191A - Metodo para sintetizar piruvil-glicina - Google Patents

Metodo para sintetizar piruvil-glicina

Info

Publication number
MX9302191A
MX9302191A MX9302191A MX9302191A MX9302191A MX 9302191 A MX9302191 A MX 9302191A MX 9302191 A MX9302191 A MX 9302191A MX 9302191 A MX9302191 A MX 9302191A MX 9302191 A MX9302191 A MX 9302191A
Authority
MX
Mexico
Prior art keywords
pyruvil
pyruvate
glycine
synthesizing
mammal
Prior art date
Application number
MX9302191A
Other languages
English (en)
Inventor
Madhup Krishna Dhaon
John Andre Houbion
Edwin Orville Lundell
Robert Harold Miller
Nickki Lynn Parlet
Kent Lee Cipollo
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX9302191A publication Critical patent/MX9302191A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención describe un método para administrar piruvato, el método comprende administrar una cantidad terapéuticamente efectiva de un precursor de piruvato a un mamífero, en forma de piruvamida o un piruvil-amino ácido. El piruvilamino ácido se selecciona preferiblemente del grupo que comprende piruvil-glicina, piruvil-alanina, piruvil-leucina, piruvil-valina, piruvil-isoleucina, piruvil-fenilalanina, piruvil-prolina y piruvil-sarcosina, y sus amidas y ésteres, así como sus sales. Asociadas con la administración de un precursor de piruvato a un mamífero de acuerdo con esta invención están la resistencia aumentada a la insulina, menores niveles de insulina al ayunar, y aumento de grasa disminuido. También se describen métodos nuevos para sintetizar varios precursores de piruvato.
MX9302191A 1992-04-16 1993-04-15 Metodo para sintetizar piruvil-glicina MX9302191A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/868,891 US5256697A (en) 1992-04-16 1992-04-16 Method of administering pyruvate and methods of synthesizing pyruvate precursors

Publications (1)

Publication Number Publication Date
MX9302191A true MX9302191A (es) 1994-03-31

Family

ID=25352516

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302191A MX9302191A (es) 1992-04-16 1993-04-15 Metodo para sintetizar piruvil-glicina

Country Status (9)

Country Link
US (4) US5256697A (es)
EP (1) EP0636117B1 (es)
JP (1) JPH082854B2 (es)
AU (1) AU3659993A (es)
CA (1) CA2130198A1 (es)
DE (1) DE69325451T2 (es)
ES (1) ES2135468T3 (es)
MX (1) MX9302191A (es)
WO (1) WO1993021147A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508308A (en) * 1992-04-16 1996-04-16 Abbott Laboratories Use of pyruvylglycine to treat ischemia/reperfusion injury following myocardial infarction
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
US5670539A (en) * 1993-07-21 1997-09-23 New York State Office Of Mental Health Treatment of movement disorders using large neutral amino acids
US5612374A (en) * 1994-02-14 1997-03-18 Ronald T. Stanko Inhibiting growth of mammary adenocarcinoma
US5480909A (en) * 1994-08-08 1996-01-02 University Of Pittsburgh Medical Center Method for inhibiting generation of free-radicals
US5550166A (en) * 1995-03-17 1996-08-27 Ostlund; Richard E. Pinitol and derivatives thereof for the treatment of metabolic disorders
US6306828B1 (en) 1995-04-06 2001-10-23 Baxter International, Inc. Enantiomerically-enhanced nutritional energy substrates
US5801198A (en) * 1995-07-13 1998-09-01 University Of Pittsburgh Medical Center Retarding neutrophil infiltration ad morphologic reduction in ischemic bowel tissues
CA2205112C (en) * 1995-09-19 2008-11-18 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
US5798388A (en) * 1996-09-06 1998-08-25 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
US5667962A (en) * 1996-03-18 1997-09-16 Case Western Reserve University Pyruvate thiolester for the prevention of reperfusion injury
US5876916A (en) * 1996-03-18 1999-03-02 Case Western Reserve University Pyruvate compounds and methods for use thereof
US6086789A (en) * 1996-03-18 2000-07-11 Case Western Reserve University Medical uses of pyruvates
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US6008252A (en) * 1996-07-26 1999-12-28 Beale; Paxton K. Method for increasing muscle mass in a mammal
US6417231B1 (en) 1996-12-23 2002-07-09 Frank L. Greenway Method and composition for delivering therapeutically effective amounts of pyruvate to a mammal
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
US5886040A (en) * 1997-06-17 1999-03-23 Amt Labs, Inc. Creatine pyruvate salt with enhanced palatability
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
AU5277000A (en) 1999-05-20 2000-12-12 Humanetics Corporation Stimulating transport of glucose into animal tissue by the administration of pinitol
US6846842B2 (en) * 1999-10-07 2005-01-25 Beth Israel Deconess Medical Center, Inc. Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion
US6864242B2 (en) 2001-03-05 2005-03-08 Stephen P. Ernest Enteral formulation
WO2002081020A2 (en) * 2001-04-04 2002-10-17 Critical Therapeutics, Inc. Method for preventing acute renal failure
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
US8076373B2 (en) * 2001-09-11 2011-12-13 North Cell Pharmacetical Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
EP1494659B1 (en) * 2002-04-17 2005-10-12 Critical Therapeutics, Inc. Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amide and lactic acid or a lactic acid salt
AU2003229016A1 (en) * 2002-05-10 2003-11-11 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagatingvaricella zoster virus and methods of use thereof
MX2007005136A (es) * 2004-11-02 2007-08-02 Oragenics Inc Metodos para regular el peso y el tamano de los animales con glicina.
AU2010276259B2 (en) * 2009-07-21 2013-04-18 Hill's Pet Nutrition, Inc. Companion animal nutrition system
US8450090B2 (en) 2009-10-06 2013-05-28 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for promoting fatty acid production in plants
CA2785642C (en) * 2009-12-29 2014-12-02 Hill's Pet Nutrition, Inc. Compositions including pyruvate for companion animals and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE372006B (es) * 1971-09-13 1974-12-09 Haessle Ab
US4197316A (en) * 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
US4296127A (en) * 1979-04-18 1981-10-20 The Johns Hopkins University Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof
IT1120033B (it) * 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
US4351835A (en) * 1981-04-01 1982-09-28 Montefiore Hospital Method for preventing body fat deposition in mammals
US4548937A (en) * 1981-04-01 1985-10-22 Montefiore Hospital Method for preventing body fat deposition in mammals
DE3438455A1 (de) * 1984-10-19 1986-06-26 Institut Dr. Ziegler, Bettingen L-lysin- und l-histidinpyruvat
FR2626276B1 (fr) * 1988-01-22 1990-05-11 Hoechst France Perfectionnement au procede de fabrication de pyruvates d'alkyle
US4874790A (en) * 1988-08-15 1989-10-17 Montefiore Hospital Association Of Western Pennsylvania Method for improving the glucose metabolism of an animal having diabetic tendencies
DE3917880A1 (de) * 1989-06-01 1990-12-06 Kali Chemie Ag Neue acylaminosaeurederivate enthaltende arzneimittel und diaetetika
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors

Also Published As

Publication number Publication date
JPH07501830A (ja) 1995-02-23
JPH082854B2 (ja) 1996-01-17
US5283260A (en) 1994-02-01
US5312985A (en) 1994-05-17
EP0636117A1 (en) 1995-02-01
AU3659993A (en) 1993-11-18
CA2130198A1 (en) 1993-10-28
US5472980A (en) 1995-12-05
WO1993021147A1 (en) 1993-10-28
DE69325451T2 (de) 2000-01-20
EP0636117B1 (en) 1999-06-23
EP0636117A4 (en) 1995-07-26
US5256697A (en) 1993-10-26
ES2135468T3 (es) 1999-11-01
DE69325451D1 (de) 1999-07-29

Similar Documents

Publication Publication Date Title
MX9302191A (es) Metodo para sintetizar piruvil-glicina
NO20071498L (no) Substituerte acylhydroksamsyrer samt fremgangsmate for a redusere TNFa-nivaet
ES2150663T3 (es) Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina.
ES2150482T3 (es) Pirazolopirimidinas como antagonistas del factor liberador de corticotropina.
AT308120B (de) Verfahren zur Herstellung neuer 2-substituierter 4-Amino-6,7,8-trialkoxychinazoline sowie der Säureanlagerungssalze dieser Verbindungen
AR246755A1 (es) Una composicion para el tratamiento de las superficies de los suelos.
RU93005334A (ru) Производные стероидов для лечения гипертрофии предстательной железы, способ их получения, использование, фармкомпозиция
AT305262B (de) Verfahren zur Herstellung neuer, linksdrehender, basisch substituierter Phenylacetonitrile sowie deren Salze
EP0451654A3 (en) Use of n-alkylated 1,4-dihydropyridine carboxylic acid esters as drugs, new compounds and process for their preparation
MX167912B (es) Metodo para la produccion de una preparacion de nicorandil estable
SE9601677D0 (sv) New use
GB1285400A (en) Esters of substituted anthranilic acid
AT277245B (de) Verfahren zur Herstellung von neuen Säureamiden, sowie von deren Salzen und optisch aktiven Isomeren
AT305263B (de) Verfahren zur Herstellung neuer, rechtsdrehender, basisch substituierter Phenylacetonitrile sowie deren Salze
AR034398A1 (es) Homologos de 15-hete con 3-heteroatomos sustituidos y dos atomos de carbono del acido hidroxieicosatetraenoico, composicion que los contiene y el uso de la misma para la manufactura de un medicamento
GB1272915A (en) Treatment and prevention of scours in livestock
FR2336369A1 (fr) Procede d'obtention d'acide glutarique, d'acide succinique et d'acide adipique a partir d'un melange acide les contenant ainsi que lesdits acides obtenus par ce procede
DE59203777D1 (en) Aminomethylencyanessigsäureester und -amide.
AT278508B (de) Verfahren zur Herstellung von Matratzen od.dgl. sowie nach diesem Verfahren hergestellte Matratze
ES2031462T3 (es) Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima.
CH490379A (de) Verfahren zur Herstellung eines Cyclopropancarbonsäureesters sowie Verwendung des nach dem Verfahren hergestellten Cyclopropancarbonsäureesters
AT318567B (de) Verfahren zur Herstellung neuer 1-Phenoxy-2-hydroxy-3-hydroxyalkylaminopropane sowie deren Säureadditionssalze und Ester
AT289752B (de) Verfahren zur Herstellung von neuen 4-Aminomethylbicyclo[2,2,2]octan- bzw. 4-Aminomethylbicyclo[3,2,2]nonan-1-carbonsäuren und deren 2,5-Diketoverbindungen, sowie deren Salzen, Estern und N-Alkanoylverbindungen
CH514571A (fr) Procédé de préparation d'esters d'acides cyclopropane-carboxyliques
CH526516A (de) Verfahren zur Herstellung von 2-Cyan-3,4,5,6-tetrachlor-benzoesäurealkylestern